Desmoid Tumor and Pregnancy: Effect of Pregnancy on Disease Control and Effect of Diagnosis on Pregnancy History.

Description

Desmoid tumors (DT) are rare disease of intermediate malignancy with variable and often unpredictable clinical course. There is a growing interest in defining potential risk of recurrence or progression during or after pregnancy and in identifying potential obstetrical risks and infertility rate of desmoid patients. Aim of the study: * to define the impact of pregnancy on diagnosis, progression and recurrence of DT; * to define the risks related to DT of obstetrical risks and decisions to interrupt or avoid pregnancy after the diagnosis of DT.

Conditions

Desmoid, Desmoid; Abdominal, Pregnancy Loss, Pregnancy Complications

Study Overview

Study Details

Study overview

Desmoid tumors (DT) are rare disease of intermediate malignancy with variable and often unpredictable clinical course. There is a growing interest in defining potential risk of recurrence or progression during or after pregnancy and in identifying potential obstetrical risks and infertility rate of desmoid patients. Aim of the study: * to define the impact of pregnancy on diagnosis, progression and recurrence of DT; * to define the risks related to DT of obstetrical risks and decisions to interrupt or avoid pregnancy after the diagnosis of DT.

Desmoid Tumor and Pregnancy: Effect of Pregnancy on Disease Control and Effect of Diagnosis on Pregnancy History. An International Multicenter Retrospective Observational Study

Desmoid Tumor and Pregnancy: Effect of Pregnancy on Disease Control and Effect of Diagnosis on Pregnancy History.

Condition
Desmoid
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham and Women Hospital / Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * histologically-proven DT;
  • * female patients
  • * fertile age, \>18 years;
  • * concomitant or subsequent pregnancy (study group), or no history of pregnancy (screening group).
  • * suspected DT without histological diagnosis • male patients affected by DT
  • * \<18 years old, and non-fertile age.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano,

Marco Fiore, MD, PRINCIPAL_INVESTIGATOR, Fondazione IRCSS Istituto Nazionale Tumori

Study Record Dates

2023-05-15